Dr. Kiran Mahasuar, Asst Professor at IMT Ghaziabad, writes why branded generics may still dominate volumes, but the real ...

The pharma and healthcare sector witnessed a 70 per cent drop in deal values to $2.1 billion in Q1 CY25 compared to the ...

To mitigate the impact of potential tariffs, market diversification strategies are essential. Indian pharmaceutical firms can ...

Executive Director, Federation of Seed Industry of India (FSII ... reflecting its unjustifiable stance on agri-biotechnology. Unfortunately, India’s approach to agri-biotechnology has ...

US market exposure limits Indian pharma's safe-haven appeal amid global volatility and tariff fears, but drugmakers focused ...

With Trump’s tariffs poised to disrupt global pharma trade, industry stakeholders see opportunities for India, provided it ...

During the review, Dr. Singh lauded the Department of Biotechnology and BIRAC for their consistent contributions to medical ...

Official data showed that the total value of pharmaceutical exports reached $30,467.32 million in FY25, rising over 9 per ...

Uncertainty surrounding US tariffs and global economic headwinds has tempered hiring in India's pharma and healthcare GCCs.

HPV test kits for cervical cancer screening were launched here on Wednesday. The test kits have been developed under the Department of Biotechnology’s (DBT) partnership programme Grand Challenges ...

Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40 ...